https://journals.ipsintelligentsia.com/medical-sciences/index.php/ijbcm/issue/feed 2025-01-03T10:39:18-07:00 Managing Editor editor@ipsintelligentsia.com Open Journal Systems <p><strong>Journal Summary: </strong><strong>Scope:</strong> Publishes in all areas of medicine. <strong>ISSN:</strong> Print and Online. <strong>DOI Prefix: </strong>Crossref. <strong>Frequency:</strong> Bimonthly (6 Issues per year). Jan, Mar, May, Jul, Sept, Nov. <strong>Journal model:</strong> Open Access. <strong>Article Processing Charges:</strong> $20 or #25,000 for local authors. <strong>Abstracting &amp; Indexing:</strong> Google Scholar, Semantic Scholar, Index Copernicus, Crossref, WorldCat. <strong>Type of articles:</strong> All kinds of articles including book of abstracts and conference proceedings. <strong>Review type:</strong> Double-blind peer review. <strong>License type:</strong> CC BY 4.0. <strong>Area of coverage: </strong>All areas of basic medicine, clinical medicine, internal medicine, tropical medicine, epidemiology, gynecology, forensic medicine, emergency medicine, medicine and surgery, medical/clinical biochemistry, physiology, anatomy, pharmacology, molecular biology, genetics, clinical nutrition, toxicology, endocrinology, medical physics, biophysics, embryology, cytology, histology, pathology, immunology, medical microbiology, neuroscience, radiobiology, biostatistics etc.</p> https://journals.ipsintelligentsia.com/medical-sciences/index.php/ijbcm/article/view/6 2025-01-03T08:34:28-07:00 Olukayode Olusola Odubela Odubela.olukayode@oouagoiwoye.edu.ng Afeez John Olanrewaju olanrewajuj@babcock.edu.ng Daniel Nsikan Nsubong olanrewajuj@babcock.edu.ng

<p>Parkinson's disease (PD), a progressive neurodegenerative disorder, is marked by dopaminergic neuronal loss in the substantia nigra and the pathological accumulation of alpha-synuclein. Current treatments primarily address symptoms without halting disease progression, underscoring the need for novel therapeutic strategies. This study investigated the effects of co-administration of luteolin and curcumin in a transgenic <em>Drosophila melanogaster</em> model of PD. Luteolin and curcumin, recognized for their antioxidant and anti-inflammatory properties, were administered to evaluate their impact on survival rates, locomotory activity, muscular integrity, and oxidative stress markers. Results demonstrated that the treated group exhibited a significant increase in survival rate and improved locomotory and exploratory activities compared to untreated mutants. The larva crawling assay revealed enhanced muscular integrity, suggesting the restoration of motor function. Biochemical assays indicated reduced malondialdehyde (MDA) levels and increased catalase and thiol activity in the treated group, highlighting the compounds' ability to mitigate oxidative stress. Molecular docking analyses revealed strong interactions between luteolin, curcumin, and key PD-related proteins, including PERK, AChE, and MAPK10, with high binding affinities and favorable binding free energy values. These findings suggest that luteolin and curcumin target pathways implicated in oxidative stress, neuroinflammation, and protein misfolding, offering a multi-targeted approach to PD therapy. This study underscores the therapeutic potential of luteolin and curcumin as complementary agents in managing Parkinson’s disease, paving the way for further exploration into their clinical applicability.</p>

2025-01-03T00:00:00-07:00 Copyright (c) 2025 Olukayode Olusola Odubela, Afeez John Olanrewaju, Daniel Nsikan Nsubong